SAN FRANCISCO, CA-- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, announced that preliminary results from The PARTNER II Trial ...

Patients in the SAPIEN 3 Ultra RESILIA valve cohort, who had an average STS score of 3.6 and average age of 77, experienced meaningful quality of life benefits with a clinically significant ...

Meeting Coverage > TCT Could Sapien Valve Weather 25 Years With Little Wear? — A billion beats in bench testing say yes. by Crystal Phend, Senior Associate Editor, MedPage Today September 26, 2019 ...

IRVINE, CA. -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark in Europe for valve-in-valve ...

The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue technology and the market-leading SAPIEN 3 Ultra transcatheter aortic heart valve. The latest launch builds on the ...

PARIS, May 19, 2015 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that the first high-risk ...

Edwards TAVR segment reached $1.1bn in Q2 2025, up 8.9% compared to Q2 2024, while its heart valve segment increased by 61.9% ...

Wood, who helped build Edwards’ TAVR business, will become CEO of Procept BioRobotics. Edwards also raised its sales and ...

Transcatheter aortic valve replacement (TAVR) with the contemporary Sapien 3 device generally held up against surgery in intermediate-risk patients over 5 years, according to a propensity-matched ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

In transcatheter aortic valve replacement for severe aortic stenosis, there were similar 1-year event rates between a self-expanding valve and a balloon-expanding valve except for stroke, which ...